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Abstract
Background: Since its recent discovery, interleukin-23 has been shown to be involved in the pathogenesis of
autoimmune diseases favoring the development of a T cell subset referred to as T helper 17. Glucocorticoids are
widely employed in inflammatory and autoimmune diseases as they inhibit pro-inflammatory signaling and
prevent production of inflammation mediators. Very limited information is available about the efficacy of synthetic
glucocorticoids in containing the expression of interleukin-23 under cell activation.
Results: We demonstrate here that the glucocorticoid analogue dexamethasone administered to human
monocyte-derived macrophages is indeed able to restrain the expression of interleukin-23 once it has been
triggered by a pro-inflammatory stimulus. This effect of dexamethasone is here demonstrated being secondary to
suppression of p38 MAPK activity, and involving a protein phosphatase - likely MAPK phosphatase-1 (MKP-1).
Conclusions: Results reported in this paper show that a 10 nanomolar dose of dexamethasone not only prevents
inflammatory activation but is also efficacious in confining active inflammation. This effect is here demonstrated
not to occur through “canonical” inhibition of the NF-B transcription factor but through a distinct cascade of
down-modulation, that underlines the importance of the transactivating activity of glucocorticoid receptor in the
context of its anti-inflammatory action.
Background
IL-23 is a heterodimeric cytokine composed of the IL-
12p40 subunit and the recently discovered IL-23p19
subunit, related to IL-12p35 [1]. The IL-23 receptor
complex is present on the surface of APC, NK and acti-
vated T cells. Despite IL-23p19 expression in different
tissues and cell types, p19 alone has not been found to
have biological activity and appears to be functional
only when dimerized with p40, which occurs in acti-
vated M and DC. Production of IL-23 by APC is trig-
gered by host immune stimuli as interferons and by
bacterial products, such as LPS, that signal through TLR
[2-4]. Whereas IL-12 drives the differentiation of T
helper 1 cells (Th1), IL-23 favors the development of a
T cells subset with a unique expression profile, charac-
terized by prominent production of IL-17, therefore
referred to as Th17 cells [5,6]. IL-17, in turn, induces
pro-inflammatory cytokines that contribute to protective
response during infection [7,8]. IL-23 is commonly
believed to act on memory CD4
+ T cells, enhancing the
expansion of committed Th17 and production of IL-17
[1,9], although it was also hypothesized that IL-23 role
is not merely limited to a survival factor. In fact, several
observations suggest that IL-23 may act earlier during
Th17 commitment, promoting their effector function
[10]. However, IL-23 is absolutely required for providing
Th17 a pathogenic phenotype, because in its absence
these cells may have regulatory functions. Nonetheless,
the IL-23/IL-17 axis is evolutionarily conserved as it
provides a rapid response to catastrophic injuries,
caused by certain infective agents (e.g. K. pneumoniae,
T. gondii, S. aureus and B. pertussis) especially in gut,
lung and skin.
Although autoimmune diseases have long been con-
sidered being T cell-mediated, the pleiotropic role of
M in immunity has lately received more attention, and
M products have been implicated in various
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strated that M-secreted IL-23, and consequently T cell-
derived IL-17, are linked to disease in animal models of
autoimmunity [11-13]. Abnormal IL-23 concentration is
found also in human biological fluids and tissues
affected by rheumatoid arthritis [14], multiple sclerosis
[15,16], psoriasis [17], inflammatory bowel diseases
[18,19]. Moreover, the IL-23/IL-17 axis plays a role dur-
ing inflammatory process-derived tumor development:
IL-23 decreases number and activity of cytotoxic T cells
in transformed tissues [20].
GC hormones modulate a wide array of physiologic
functions, especially in the context of immune homeosta-
sis. Therefore, synthetic GC are broadly employed for
treatment of inflammatory conditions. Suppression of
inflammation by GC is believed to occur through three
main mechanisms: non-genomic pathways, direct genomic
effects and indirect genomic effects [21]. Ligand-bound
GR regulates target genes expression by interaction with
GRE. However, genes regulated through this direct inter-
action are much less (1%) than genes whose expression is
indirectly regulated. In fact, the GR is able to influence -
mainly inhibit - the activity of several pro-inflammatory
transcription factors, including NF-B, AP-1, t-BET,
STAT5 [22,23]: in the promoter environment of pro-
inflammatory genes, active GR competes for binding to
co-activators, affects RNA polymerase II activity, interacts
with co-repressors and hystone de-acetylases, specifically
modulating the expression of each gene. Besides affecting
transcription, GC reduce post-transcriptional stability of
particular sets of mRNA, thus dampening the synthesis of
inflammatory proteins after the inflammation has been
activated [24-26]. The synthetic GC analog DEX has
higher affinity for the receptor, higher anti-inflammatory
activity and a longer biological half-life than conventional
steroids [27]. As for the effects of DEX on IL-23 signaling,
it is demonstrated that the GC analogue affects activation
of STAT4 induced by IL-23 in PHA/IL-2 T cells [28], and
a study by Ma et al. shows that DEX inhibits LPS-induced
IL-12p40 production in human monocytes [29].
Given the critical role of deregulated IL-23 production
in pathogenesis, we investigated in vitro the effect that
DEX exerts on expression of IL-23 - in particular, of its
unique p19 subunit - by human M.M o r e o v e r ,s i n c e
NF-B and p38 MAPK are involved in the regulation of
IL-23p19 expression in various cell types of the mono-
cyte/M lineage [30-33], we focused on the mechanism
of DEX inhibition on these pathways with respect to
down-modulation of IL-23p19.
Results
DEX reduces IL-23 levels in vitro
Primary cultured human M were first subjected to stimu-
lation with LPS in order to assess the time course of IL-23
expression in response to the engagement of TLR-4.
Although distinct subjects respond diversely in terms of
fold induction, they all show a peak level of IL-23p19
mRNA after 8h of persistent stimulation with LPS (Figure
1A), which is followed by increase of the protein between
8h (lane 2) and 24h (lane 3) (Figure 1B). Therefore, we
consider cultured M persistently stimulated with LPS for
8h a suitable in vitro model of established IL-23 expression.
The ability of DEX to restrain ongoing IL-23 expression
was next evaluated adding the drug during the last 2h of
LPS treatment: M stimulated 6h with LPS were either
left untreated or treated with 0.001, 0.01, 0.1 or 1 μM
DEX, and maintained at 37°C for additional 2h in the pre-
sence of LPS. Relative quantification by RT-PCR revealed
that, while DEX 0.001 μM does not exert any effect on IL-
23p19 expression, DEX 0.01 μM induces a significant
decrease in the amount of p19 mRNA compared to DEX-
untreated samples (Figure 1C). A similar reduction occurs
with 0.1 and 1 μM DEX. On the same samples, the expres-
sion of other IL subunits strictly related to IL-23p19 was
evaluated and compared by relative quantification, demon-
strating that 0.01 μM is the least DEX concentration able
to significantly down-regulate IL-12p40 and IL-12p35
mRNA (Figure 1D and 1E). On the other hand, a consis-
tent up-regulation of FKBP5 mRNA was observed with
doses ≥ 0.01 μM, demonstrating the effective activation of
the GR signaling pathway (Figure 1F).
We then attempted at validating IL-23 expression data
also on the protein product, by an IL-23 ELISA on M
supernatants collected at 8, 16 and 24h of LPS stimula-
tion, either treated or not with DEX. Unfortunately, the
amount of protein was below the limit of sensitivity of
the kit, and this problem could not be circumvented by
concentrating the samples.
However, the effect of DEX on IL-23 protein production
was verified at the intracellular level by western immuno-
blotting of the IL-23p19 subunit. Human M were stimu-
lated 6h with LPS and then either added with 0.01 μM
DEX or left DEX-untreated for additional 2h, then all the
compounds were removed and total cell lysates were pre-
pared at 24h. As shown in Figure 2, DEX added during IL-
23p19 gene transcription leads to a significant decrease of
the protein product (lanes 3, 4), confirming the data
observed at the transcriptional level and suggesting that
the drug can be effective in reducing the amount of
secreted interleukin. Interestingly, DEX was also able to
prevent IL23-p19 protein accumulation induced in human
M by a distinct pro-inflammatory agonist, Zymosan from
Saccharomyces cerevisiae (data not shown).
DEX does not affect nuclear localization or DNA-binding
of active NF-B
Transcription factor NF-Bc a nb er e g u l a t e db yv a r i o u s
events and at distinct levels of the activation cascade.
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tion through interaction with a member of the IB
family. Immunofluorescence directed to the p65 subunit
of NF-Bw a sp e r f o r m e do nM  stimulated 6h with
LPS and then either added with 0.01 μM DEX or left
DEX-untreated for additional 2h. As shown in Figure
3A (left box), nuclear-cytosolic shuttling of p65 is
shifted toward nuclei after 8h of LPS treatment. How-
ever, addition of DEX does not produce any significant
reduction of the nuclear signal (Figure 3A, right box).
Consistent with these results, we observed that none
of the tested concentrations of DEX actually up-
Figure 1 DEX affects IL-23 mRNA levels. (A) Time course of IL-23p19 expression in M stimulated with 1 μg/ml LPS for the indicated times.
Relative quantification was performed by Real Time RT-PCR according to the ΔΔCt comparative method and data are expressed as fold changes
compared to the peak sample (LPS 8h). Data reported in diagram are the average of three independent experiments. (B) Time course of IL-23p19
protein accumulation in M after 24h of stimulation with 1 μg/ml LPS. Western immunoblotting were performed on total cellular extracts. Images
are representative of three independent experiments and data are reported in bar graph as fold changes compared to the peak sample (LPS 24h).
IL-23p19 signal (upper panel) was normalized to the actin signal (lower panel). (C),(D),(E) DEX-dependent inhibition of expression of the interleukin
subunits IL-23p19, IL-12/IL-23p40 and IL-12p35, respectively. Real Time RT-PCR was performed on LPS-stimulated M treated with increasing
concentrations of DEX. Results are reported as raw 2^-(Ct target-Ct reference) to compare the relative abundance of each subunit. Amplification
efficiencies of p19 and p35 were comparable, based on the slopes of their standard curves. n = 3. (F) Induction of FKBP5 by DEX in M treated as in
(C). Real Time RT-PCR data are reported as fold changes compared to the DEX-untreated sample; n = 6. * p < 0.05, ** p < 0.01.
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tein, after 8h of LPS stimulation (Figure 3B), indicating
that the lower IL-23p19 expression is not secondary to
cytosolic retention of NF-B. Nonetheless, it could be
the consequence of an impaired DNA-binding activity
of NF-B, therefore we performed NF-B EMSA on M
treated as for immunofluorescence (Figure 3C). We
observed that the DNA-binding activity of NF-B before
addition of the drug (LPS 6h, lane 2) is up to twice (1.8
±0 . 6 ,p < 0.01, n = 12) that of basal cells (lane 1); when
IL-23p19 mRNA is on its peak level (LPS 8h, lane 3)
NF-B activation remains indeed high (1.7 ± 0.4, p <
0.05, n = 12), but is not inhibited by DEX (lane 4) (1.7
±0 . 4 ,p < 0.05, n = 12). Surprisingly, the amount of
IBa analyzed on the same cellular extracts (Figure 2D)
reflects the transcriptional activity of NF-B rather than
its inhibition. In fact, after 6h of stimulation (lane 2) the
amount of IBa is up to five fold that of basal M (lane
1) (4.6 ± 0.7, p < 0.01, n = 4), it remains high at 8h
(lane 3) (3.2 ± 2.3, p < 0.01, n = 4) and it is almost unaf-
fected by DEX (lane 4) (3.1 ± 1.8, p < 0.05, n = 4).
DEX reduces the transactivation ability of activated NF-B
To confirm and elucidate the effect of DEX on NF-B, a
reporter cell line was employed. MM6 cells transfected
with the LUC coding sequence under NF-Bt r a n s c r i p -
tional control, were stimulated with LPS over a time
course of 8h. At 2h LUC mRNA is at peak level,
whereas the maximum of LUC activity is observed at 6-
7h (not shown). Since our goal is to evaluate DEX activ-
ity on pre-existing inflammatory conditions, we stimu-
lated reporter cells 1h with LPS to trigger LUC
expression. Afterward, cells were treated with DEX 0,
0.001, 0.01, 0.1 or 1 μM for one more hour in presence
of LPS. Culture medium was then replaced and cells
were left at 37°C for additional 5h (Figure 3E). At the
end of treatment the luminescent signal is high com-
pared to basal reporter cells, confirming the activation
of NF-B. Whereas DEX 0.001 μM has no effect on the
reporter activity, a significant reduction of LUC signal is
detectable with DEX ≥ 0.01 μM.
Western immunoblotting for p65 was performed on
nuclear and cytosolic extracts from the same cells, to
exclude that the lower level of reporter activity was due
actually to cytosolic sequestration of NF-B. As
expected, nuclear NF-B-p65 increases - and the cytoso-
lic decreases - as cells are stimulated with LPS, but the
DEX concentrations tested do not modify the sub-cellu-
lar localization of p65 to an extent significantly consis-
tent with the reduction of reporter activity (Figure 3F).
Therefore, we conclude that DEX reduces the transacti-
vation potential of active NF-B, because expression of
its target gene is down-modulated although the tran-
scription factor remains localized to the nucleus.
DEX down-modulates p38 MAPK activity
Because p38 MAPK usually promotes NF-Bt r a n s -
activity, we speculated that the results above described
could arise from p38 impairment by DEX. Thus, in
LPS-stimulated M, increasing concentrations of drug
were tested on the extent of p38 MAPK phosphoryla-
tion, on that of NF-B p65 phosphorylation on serine
residue 276 (Ser276), and on the expression of MAPK
phosphatase-1 (MKP-1), a negative regulator of MAPK.
Western blotting was performed on the same type of
samples employed for analyses of IL-23 expression.
Accordingly, the decreased IL-23 expression is accompa-
nied by a consistent reduction of p38 MAPK phosphor-
ylation. Again, 0.01 μMD E X( F i g u r e4 A ,l a n e3 )
promotes a significant dephosphorylation of p38 com-
pared to the control sample (lane 1) and 0.1 and 1 μM
DEX (lanes 4, 5) yield similar results. Interestingly, the
phosphorylation of p65(Ser276) was decreased with an
apparent dose-trend relationship, consistent with the
reduction of p38 MAPK activity (Figure 4B).
MKP-1 levels were evaluated by RT-PCR on M
under the same experimental conditions as above. As
expected, LPS promotes a five-fold increase of MKP-1
mRNA compared to basal M, and DEX administered
to the cells during the last 2h of stimulation further
enhances MKP-1 expression. In particular, consistent
with what above described, at least 0.01 μMD E Xi s
Figure 2 DEX affects IL-23 protein levels. DEX (0.01 μM) reduces
IL-23p19 protein production. IL-23p19 protein was analyzed by
western immunoblotting of M stimulated with LPS (upper panel)
for the times indicated. Data obtained from densitometric analyses
were normalized on respective actin signals (lower panel). Images
are representative of three independent experiments and data are
reported in bar graphs as fold changes relative to the peak samples;
n = 3. *p < 0.05
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Page 4 of 12Figure 3 Mechanism of NF-B activity restraint by DEX. (A) Immunofluorescence analyses of NF-B-p65 sub-cellular localization. FITC pictures
show p65 signal in two representative fields of M stimulated 8h with LPS (left box) or of M stimulated 8h with LPS and treated with 0.01 μM
DEX (right box). DAPI:FITC pictures were obtained by overlay of the FITC and DAPI signals, and show the nuclear localization of p65. (B). LPS-
stimulated M (lane 1) were treated with increasing concentrations of DEX (lanes 2-5) and the amount of IBa was analyzed by western
immunoblotting (upper panel), normalized to the actin signal (lower panel). Image is representative of three independent experiments. (C). M
(lane 1, 0h) were subjected to NF-B EMSA after LPS stimulation for 6h (lane 2) and 8h, in presence (lane 4) or absence (lane 3) of DEX 0.01 μM. The
image is representative of four independent sets of samples, each run in triplicate. (D) IBa western immunoblotting on the same samples
employed for EMSA, representative of four independent experiments. (E) NF-B reporter assay on MM6 cells. NF-B-driven transcription was
triggered by LPS 1 μg/ml for 1h, followed by treatment with indicated DEX concentrations. Data of relative light units/μg of proteins are reported
in bar graph as fold changes compared to the DEX-untreated sample (+LPS, 0 DEX); n = 12. (F) NF-B p65 western immunoblotting on cytosolic
and nuclear extracts from the same cells as in (E). Densitometric analysis was followed by normalization on the internal control represented by
actin. Data are reported in bar graphs as fold changes relative to the DEX-untreated sample (lane 2); n = 6. * p < 0.05, ** p < 0.01.
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transcript over the level of the DEX-untreated sample,
and this induction is maintained by DEX 0.1 and 1 μM
(Figure 4C). Furthermore, the involvement of a phos-
phatase activity in the reduction of NF-B transactiva-
tion potential by DEX was demonstrated on MM6
cells using the phosphatase inhibitor Na3VO4.M M 6
reporter cells were stimulated 1h with LPS and then
treated with DEX 0, 0.01, 0.1 or 1 μM, added alone or
along with Na3VO4 for 1h more, in presence of LPS.
The medium was then replaced and cells were left at
37°C for additional 5h. Increasing concentrations of
DEX promote a significant reduction of the lumines-
cent signal compared to DEX-untreated cells, whereas
the phosphatase inhibitor counteracts the trend of
such DEX-mediated decrease, as cells treated with
Figure 4 DEX down-modulates p38 MAPK activity. (A) DEX-dependent inhibition of p38 MAPK was measured in LPS-stimulated M by
western immunoblotting of the phosphorylated protein (phospho Thr180/Tyr182), normalized on the total amount of p38. Data are reported in
bar graph as fold changes relative to the DEX-untreated sample (lane 1); n = 3. (B) Inhibition of NF-B-p65 transactivity by DEX was measured in
LPS-stimulated M by western immunoblotting of p65 phosphorylation on Ser276, normalized on the total amount of p65. Data are reported in
bar graph as fold changes relative to the DEX-untreated sample (lane 1); n = 3. (C) DEX-induced increase of MKP-1 mRNA determined by RT-PCR
on the same samples as in (A). Data are reported as fold changes relative to the DEX-untreated sample (lane 1); n = 6. (D) Bar graph shows data
from luciferase assays performed on MM6 reporter cells, stimulated with LPS and treated with increasing concentrations of DEX, administered
alone or with sodium orthovanadate. Data are reported as fold changes relative to the DEX-untreated sample (+LPS, 0 DEX); n = 15. (E) Bar
graph shows RT-PCR data for the IL-23p19 transcript from M stimulated with LPS and then treated or not with DEX 0.01 μM alone or along
with sodium orthovanadate. Data are reported as fold changes relative to the DEX-untreated sample (8 hLPS, - DEX, -Na3VO4); n = 6. * p < 0.05,
** p < 0.01.
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treated with DEX alone (Figure 4D).
Similarly, the link between phosphatase induction
and IL-23p19 down-modulation was assessed in M,
administering Na3VO4 along with DEX. M were sti-
mulated 6h with LPS and then either left untreated or
treated with DEX 0.01 μM in the presence or absence
of Na3VO4 for additional 2h. RT-PCR revealed that
DEX produces a decrease of IL-23p19 consistent with
that previously observed, compared to DEX-untreated
M, whereas addition of the Na3VO4 along with DEX
impedes such decrease, yielding an amount of tran-
script significantly more abundant not only than that
of DEX-treated M but also of control (p <0 . 0 5 ,n=
6) (Figure 4E).
Discussion
The anti-inflammatory and immunosuppressive proper-
ties of GC are attributed to their ability of down-regulat-
ing pro-inflammatory pathways, such as those of MAPK,
AP-1 and NF-B, and preventing production and/or
release of several pro-inflammatory factors by a variety
of cell types challenged with different stimuli [29,34,35].
During the last decade numerous studies have demon-
strated that aberrant expression of IL-23 and of its
downstream partner IL-17 underlie development and
maintenance of autoimmunity. The requirement of IL-
23 for Th17 cells to acquire a pathogenic phenotype
links unquestionably IL-23 to disease but, to our knowl-
edge, the outcome of DEX treatment on the mechan-
isms of IL-23 expression is as yet unexplored. Many in
vitro studies on the effects of DEX perform either a
drug treatment -spanning between 30 min to 2h- before
activation of inflammatory pathways, or a co-treatment
with DEX and pro-inflammatory agonists [29,35-37].
Instead, we reasoned that the performance of DEX
could be different if administered after the inflammation
has been triggered; therefore, in a therapeutic perspec-
tive, we considered more interesting to verify the effi-
cacy of the drug in restraining - rather than preventing
- IL-23 expression under active pro-inflammatory sig-
naling. Thus, in our model IL-23p19 expression is sti-
mulated by LPS (Figure 1A and 1B), then the drug is
added during the phase of maximal accumulation of the
transcript, before its physiological decay. Four loga-
rithms of DEX sub-micromolar concentrations (0.001 to
1 μM) were tested, and the engagement of the GC sig-
naling pathway was verified by the up-regulation of
FKBP5, a GR target gene known to be expressed in
response to GC as part of the GR auto-regulatory loop
[38] (Figure 1F).
We show that at least 0.01 μM DEX is necessary to
engage GR (Figure 1F) and to produce a significant
reduction of IL-23p19 (Figure 1C). In fact, 0.01-0.1 μM
are DEX concentrations within the physiologically and
therapeutically relevant range for GR-mediated actions
[35,39]. However, the results obtained with DEX 0.01
μM are not improved by higher doses, and this may ori-
ginate from a saturation effect, hypothesis supported by
t h ee v i d e n c et h a ta0 . 0 1μM plasma concentration of
DEX is sufficient to saturate more than 80% of the GR
[40].
DEX 0.01 μM reduces the expression of IL-12p40 and
IL-12p35 as well (Figure 1D and 1E, respectively). Actu-
ally, high level production of functional IL-12 by human
monocytes, M and DC requires interferon-g in addition
to microbial stimuli [4,32]. However, this does not
exclude that LPS alone may trigger IL-12 expression,
though to a lesser extent. In fact, we show that both
p40 and p35 are induced by LPS treatment, but p35 is
expressed at a level two orders of magnitude lower than
p19, based on the respective amplification efficiencies.
Unfortunately, since the amplification efficiency of IL-
12p40 is not comparable with those of p19 and p35, we
cannot make any statement about its relative abundance.
However, from these observations we conclude that a
physiologic dose of DEX is able to dampen ongoing
expression of both IL-23 subunits, through inhibition of
the signaling pathways that govern the transcription
triggered by microbial stimuli. Moreover, the transcrip-
tional down-modulation of IL-23p19 is here demon-
strated to yield a comparable decrease of the protein
amount, leading to the conclusion that DEX effectively
impairs the ability of producing IL-23 in human M
(Figure 2). Therefore, we aimed at identifying the main
molecular mechanisms at the basis of IL-23 reduction
by DEX.
Consistent with the typical TLR signaling, we have
recently shown that NF-B activity is required for IL-23
expression in LPS-stimulated human M [33]. Thus, we
focused on the NF-B signaling pathway, which DEX
inhibits at multiple levels. The transcriptional up-regula-
tion of IBa has long been known to play a major role
in GC-mediated repression of NF-B, especially in cer-
tain cell types [41]. Our research group have demon-
strated that in M DEX up-regulates IBa,w h i c h
prevents NF-B triggering by LPS [37]. Instead, when
DEX is added over a pre-existing activation of the path-
way, down-modulation of pro-inflammatory transcripts
is not accompanied by a consistent cytosolic sequestra-
tion of NF-B (Figure 3A). In fact, DEX does not affect
amount of IBa neither at the transcription level nor at
that of translation (Figure 3B). Actually, LPS up-regu-
lates IBa, which is already up to four times more
abundant than in basal M when DEX is added to cells
(Figure 3D); thus, it is likely that DEX is not able to
further enhance IBa expression. Nonetheless, such
high amount of IBa seems not to be sufficient or
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persistent TLR signaling. In agreement, when NF-B
activation is explored by EMSA (Figure 3C), clearly
results that DEX does not impair transcription factor
binding to target DNA.
Although the relevance of IBa up-regulation in GC
anti-inflammatory action has been questioned [42,43],
our opinion is that it may rather depend on the timing
of drug intervention with respect to activation of pro-
inflammatory pathways. Accordingly, we verified on a
cell-based reporter system that expression of a NF-B
reporter gene is indeed down-modulated upon addition
of DEX during LPS stimulation (Figure 3E), in a fashion
that does not imply diminished nuclear distribution of
the transcription factor (Figure 3F) and hence suggests
that NF-B transactivation ability is decreased.
In synthesis, data from the MM6 cells parallel those
from M in indicating that 0.01 μM is the least DEX
concentration, among those tested, effective in tethering
NF-B pro-inflammatory activity triggered by LPS. In
addition, M data demonstrate that 0.01 μMD E X
diminishes IL-23 expression while leaving unaffected
NF-B activity in terms of nuclear localization or DNA-
binding; rather, data from the MM6 reporter system
suggest that, in an ongoing inflammatory state, DEX
acts through reduction of NF-B trans-activity.
Besides NF-B, p38 MAPK regulates inflammation
through both transcriptional and post-transcriptional
mechanisms, and MAPK inhibition has been suggested
as a promising anti-inflammatory approach [44,45].
Indeed, p38 MAPK-dependent phosphorylation of pro-
teins in the transactivation complex favors NF-B activ-
ity [46]. For example, MSK1 (mitogen- and stress-
activated kinase 1), a downstream target of p38 MAPK,
phosphorylates serine 276 of p65 enhancing transcrip-
tion [36]. In addition, p38 favors inflammation also by
post-transcriptional stabilization of pro-inflammatory
mRNAs that contain adenylate/uridylate-rich elements
in the 3’ untranslated region [47-49].
We demonstrate that a decrease of p38 MAPK phos-
phorylation takes place in LPS-stimulated M upon
administration of DEX ≥ 0.01 μM (Figure 4A). Ser276
phosphorylation on NF-B-p65 normally occurs follow-
ing activation of p38 MAPK and ERK [50]. As expected,
the down-modulation of p38 MAPK is accompanied by
a consistent diminution of Ser276 phosphorylation (Fig-
ure 4B). Although the role of ERK has not been
explored in this work, these results strongly support the
involvement of p38 MAPK inhibition in the mechanism
of DEX-induced restraint of NF-B trans-activity and of
pro-inflammatory gene expression.
Recent works have focused on the role of MAP kinase
phosphatase 1 (MKP-1) in the context of GC anti-
inflammatory function. MKP-1 is induced by GC, in fact
DEX raises MKP-1 levels in various cell types [51,52].
This phosphatase acts on p38, JNK and ERK, thereby
terminating their activation. According to the model
here depicted, we show a DEX-dependent up-regulation
of MKP-1 (Figure 4C), consistent with the decrease of
p38 and p65 phosphorylation. Moreover, addition of
Na3VO4, a phosphatase inhibitor, counteracts the effect
of DEX on NF-B transactivation ability, demonstrating
that dephosphorylation of substrates is necessary for the
accomplishment of DEX function (Figure 4D). The same
mechanism likely applies to the specific expression of
endogenous IL-23p19 in M, because the restraint
caused by DEX 0.01 μM is completely prevented by
Na3VO4 (Figure 4E).
Because we demonstrated that DEX causes inactiva-
tion of p38 MAPK, and p38 favors stability of pro-
inflammatory transcripts, we next asked whether the
lower amount of IL-23p19 results exclusively from
reduced expression - secondary to reduced NF-B activ-
ity - or is actually due to a combination of both
impaired synthesis and enhanced degradation. The
decay of IL-23p19 mRNA, in the presence or absence of
DEX, was analyzed by mRNA decay assays with the
inhibitor of gene expression ActD (data not shown). In
our experimental approach ActD is added after 30 min
from addition of DEX, to allow MKP-1 up-regulation.
Unfortunately, due to such particular timing of the
assay, we could not conclude whether the rapid (within
30 min) decay in presence of DEX can be ascribed also
to enhanced post-transcriptional destabilization of p19
mRNA. A possibility exists that DEX is only capable of
preventing stabilization of mRNA-protein complexes,
but not of destabilizing pre-existing stable complexes
[53]. In light of this, the decreased amount of IL-23p19
may result from failing stabilization of newly synthesized
mRNA.
In sum, we show here for the first time that a 0.01 μM
concentration of DEX reduces the expression of IL-23
by restraining NF-B transactivation ability. We demon-
strate that NF-B trans-activity is reduced by loss of
Ser276 phosphorylation on p65, and that this is suffi-
cient to switch off the expression of an exogenous NF-
B target gene as well as of the endogenous IL-23p19.
We show that this effect requires a phosphatase activity,
suggesting that it is mediated by p38 MAPK inhibition,
achieved through MKP-1 induction by DEX. From a
therapeutic point of view, this latter point is particularly
relevant in light of the overexpression of p38a by M of
the intestinal lamina propria from inflammatory bowel
disease patients [54].
While this paper was in preparation, it was shown that
expression of IL12p40 is regulated by a ternary NF-B
complex composed of p65, c-Rel and an hypopho-
sphorylated form of IBb that stabilizes the
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Page 8 of 12transcription factor [55]. Therefore, it will be intriguing
to verify whether IBb plays a role in IL-23p19 expres-
sion, and eventually to explore the impact of DEX on
the phosphorylation status of IBb.
Conclusions
Since continuous priming and recruitment of new T
cells into the effectors pool underlies chronic autoim-
munity and is involved in the relapsing nature of dis-
eases, gains of interest the rationale of IL-23
neutralization to prevent relapsing-remitting autoimmu-
nities [56]. To this regard, the efficacy of DEX treatment
in vitro is here demonstrated, with interesting implica-
tions from a therapeutic perspective.
Novel GR ligands that selectively promote transrepres-
sion but not transactivation have been proposed to
maintain anti-inflammatory effects while causing fewer
side effects; however, our findings show that DEX-
engaged GR induces an anti-inflammatory factor, MKP-
1, indeed supporting the opinion that dimerization-defi-
cient GR ligands might not be effective [57], as anti-
inflammatory functions of GR are not independent of its
dimerization and transactivation activity.
Methods
Cell cultures and reagents
Human monocyte-derived M were obtained from
healthy blood. Adult volunteers signed an informed con-
sent form before donation at the blood collection centre
of Hospital S. Maria della Misericordia of Urbino (Italy),
and samples were provided as anonymous. M were
prepared by density gradient separation using Lympho-
prep solution (specific density, 1.077; Axis-Shield PoC
AS, Oslo, Norway). Cells were resuspended in RPMI-
1640 medium supplemented with 10% (v/v) heat-inacti-
vated FBS, 100 U/ml penicillin, 100 μg/ml streptomycin
and 2 mM L-glutamine. Monocytes were separated by
plastic adherence to tissue culture dishes (Sarstedt AG
& Co., Nümbrecht, Germany) and/or chamber slides
(Nalge Nunc International, Termo Fisher Scientific,
Rochester, NY, USA), overnight at 37°C in a humidified
5% CO2 atmosphere. Non-adherent cells were removed
by repeated washes. Cells were cultured for 7 days, after
which > 95% of adherent cells were differentiated M,
as revealed by immunostaining and surface marker
analyses.
MM6 cells, derived from human acute monocytic leu-
kemia, were obtained from DMSZ GmbH (Braunsch-
weig, Germany) and cultured at a density of 0.5-1 × 10
6
cells/ml in a 5% CO2 atmosphere at 37°C, in RPMI-
1640 supplemented with 10% heat-inactivated FBS, 2
mM L-glutamine, 100 μg/ml streptomycin, 100 U/ml
penicillin, 1 × non-essential aminoacids, 9 μg/ml insulin
(Sigma-Aldrich, St. Louis, MO, USA), 1 mM sodium
pyruvate. All cell culture reagents were from Lonza
(Basel, Switzerland).
MM6 cells were transfected with a vector containing
the luciferase coding sequence downstream of four tan-
dem repeats of the -B consensus element. Transfection
was performed with Effectene Transfection Reagent
(Qiagen GmbH, Hilden, Germany), according to manu-
facturer’s instructions.
Approximately 10^6 monocyte-derived M,o r1 0 ^ 6
MM6 reporter cells, were stimulated with 1 μg/ml of
LPS (serotype 0111:B4, Sigma-Aldrich), for the times
indicated. DEX (Sigma-Aldrich) was resuspended in PBS
to 1 mM and working dilutions were dosed spectrofoto-
metrically at 239 nm. Na3VO4 (Sigma-Aldrich) was acti-
vated according to the standard procedure prior to use
at a final concentration of 250 μM.
Immunofluorescence
The p65 subunit of NF-B was detected in human M
by indirect immunofluorescence. 5 × 10
4 cells were
washed in PBS, fixed with 4% formaldehyde in PBS for
20 min at room temperature, and permeabilized with
0.5% NP-40 in PBS for 10 min. Samples were blocked
with 1% (w/v) BSA and 0.1% (w/v) gelatin in PBS for
1h, then incubated 1h at room temperature with a rab-
bit polyclonal anti-p65 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), 1:100 in 1% BSA/PBS. Secondary anti-
body was a FITC-conjugated goat anti-rabbit IgG
(Sigma-Aldrich) 1:300 in 1% BSA/PBS, incubated 1h at
room temperature. DNA was stained with DAPI (Sigma-
Aldrich) at a final concentration 0.2 μg/ml. Samples
were fixed in gelvatol and observed with an Olympus
IX51 Fluorescence Microscope. FITC and DAPI images
were compared by overlay.
RT-PCR
Total RNA from M was prepared with RNeasy Plus
Extraction kit (Qiagen) following the manufacturer’s
instructions. 0.5 μg of RNA was reverse transcribed in a
reaction mix assembled as described in [58]. Real Time
PCR analyses were performed in an ABI PRISM 7700
Sequence Detection System 1.9 (Applied Biosystems,
Life Technologies, Carlsbad, CA, USA). PCR reactions
were assembled in a 25 μl volume using the Hot Rescue
Real Time PCR SYBR Green Kit (Diatheva, Fano, Italy)
and 0.2 μM of each primer. Primer oligonucleotides
were purchased from Sigma-Aldrich and sequences are
reported in Table 1. For each sample three replicates
were run, corresponding to 10 nanograms of total RNA.
Thermal cycling was performed as follows: 10 min at
95°C; 45 cycles of denaturation at 95°C for 15s, anneal-
ing for 30s at the temperatures indicated in Table 1 and
extension at 72°C for 30s. At the end of PCR cycles, a
melting curve was generated to verify the specificity of
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mRNAs was performed according to the ΔΔCt com-
parative method.
Assay of IL-23 production
10
6 M, plated as above described, were stimulated for
6h with 1 μg/ml LPS, and either treated or not with DEX
for two more hours. The culture medium was collected
at 8h or replaced and collected at 16 or 24h. IL-23 con-
centration was measured with the IL-23 Heterodimer
Immunoassay kit, according to manufacturer’si n s t r u c -
tions (Invitrogen Life Technologies, Carlsbad, CA, USA).
Western immunoblotting and EMSA
Denatured whole cell extracts for western blotting ana-
lyses and native whole cell extracts for EMSA were
prepared as elsewhere described [58] and protein con-
centration was determined according to the Lowry [59]
and Bradford [60] methods, respectively. Cytosolic and
nuclear extracts from MM6 cells were prepared as fol-
lows: cells were collected in microfuge tubes and pel-
leted, washed with ice-cold PBS and incubated 10 min
on ice in buffer A (10 mM Hepes/KOH, pH 7.9, 1.5
mM MgCl2,1 0m MK C l ,0 . 5m MD T T ,0 . 5m M
P M S F ,0 . 2m ME D T A ,1 0μg/ml leupeptin, 10 μg/ml
pepstatin, 0.1% Nonidet P-40). Lysates were then cen-
trifuged 10 min at 12,000 rpm, 4°C. The cytosolic frac-
tion was removed to fresh tubes whereas pelleted
nuclei were resuspended in buffer B (20 mM Hepes/
KOH pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM
MgCl2, 0.5 mM DTT, 0.2 mM EDTA, 0.5 mM PMSF,
10 μg/ml leupeptin, 10 μg/ml pepstatin), incubated 20
min on ice and centrifuged 10 min at 12,000 rpm, 4°C,
finally collecting the supernatants (nuclear extracts) in
fresh tubes.
Western blotting was performed on cell extracts (15-
60 μg, depending on the protein of interest) diluted in 2
× sample buffer, boiled, subjected to 10% SDS-polyacry-
lamide gel electrophoresis, and electrotransferred to a
0.2 μm nitrocellulose membrane (Bio-Rad, Hercules,
CA, USA). The membrane was then blocked with 5%
non-fat dry milk or 5% BSA in TBS-0.1% Tween-20
(Sigma-Aldrich). Antibody against IL-23p19 was a
mouse monoclonal from BioLegend (San Diego, CA,
USA). IBa (C-21) and p65 (C-20) Ab were rabbit poly-
clonal from Santa Cruz Biotechnology and for a loading
control a rabbit polyclonal anti-actin (Sigma-Aldrich)
was utilized. Phosphorylation of p65 was determined
with a Phospho-Ser276-specific rabbit polyclonal Ab
(#3037), whereas that of p38 MAPK was determined
with a Phospho-Thr180/Tyr182-specific mouse mono-
clonal Ab (#9216) and with a p38 rabbit polyclonal Ab
(#9212) (Cell Signaling Technology, Boston, MA, USA).
Secondary anti-rabbit and anti-mouse HRP-conjugated
Ab were from Bio-Rad and ECL reagents were from GE
Healthcare (Little Chalfont, UK). Densitometric analyses
were performed with the ChemiDoc System (Bio-Rad).
NF-B EMSA reactions were assembled as in [58] with
10 μg of native whole cell extracts. DNA-protein com-
plexes were resolved by electrophoresis on 5% non-dena-
turating polyacrilamide gels, in a TBE buffer system, at a
constant voltage of 170 V, for 3 h at 4°C. Gels were then
d r i e da n ds u b j e c t e dt oa u t o r a d i o g r a p h yi nt h eG S 2 5 0
Molecular Imager system, followed by densitometric ana-
lysis with the Molecular Analyst software (Bio-Rad).
LUC assay
LUC assays were performed with the Luciferase Assay
System (Promega, Madison, WI, USA) according to the
manufacturer’s instruction. Briefly, at the end of the
treatment cells were collected, washed in ice cold PBS
and lysed in 1 × Reporter Buffer. 10 μl of cleared lysate,
corresponding to 10-20 μg of proteins, were read in a
96-well plate luminometer (BMG Labtech GmbH,
Offenburg, Germany). The luminescent signal was nor-
malized to the total amount of proteins per well, deter-
mined according to the Bradford method.
Statistical analysis
Data are reported as the average ± s.d. of at least three
independent experiments and - unless otherwise stated -
are expressed as fold changes relative to the calibrator
sample each time indicated. The Friedman statistical
test was followed by the Dunn’sm u l t i p l ec o m p a r i s o n
and a p value < 0.05 was considered to be significant.
Abbreviations
Ab: antibody; ActD: actinomycin D; APC: antigen presenting cell; DC:
dendritic cell; DEX: dexamethasone; GC: glucocorticoid; GR: glucocorticoid
Table 1 PCR amplification primers
Target gene Primer sequences Ta
(°C)
FKBP5 Fwd 5’-CCCTCGAATGCAACTCTCTT-3’
Rev 5’-TCTCCTTTCCGTTTGGTTCT-3’
62
GAPDH Fwd 5’-TGCACCACCAACTGCTTAG-3’
Rev 5’-GATGCAGATGATGATGTTC-3’
57
IL-12p35 Fwd 5’-CATGCTGGCAGTTATTGA-3’
Rev 5’-AAGTATGCAGAGCTTGATTTT-3’
57
IL-12p40 Fwd 5’-AGGAGAGTCTGCCCATTGAGG-3’
Rev 5’-GACCTCCACCTGCCGAGAA-3’
65
IL-23p19 Fwd 5’-CGTCTCCTTCTCCGCTTCA-3’
Rev 5’-GTGCCTGGGGTGGTAGATTT-3’
65
MKP-1 Fwd 5’-AGCAGAGGCGAAGCATCATC-3’
Rev 5’-CCCAGCCTCTGCCGAAC-3’
61
a) Fwd: forward primer.
b) Rev: reverse primer.
c) Ta: annealing temperature.
d) GAPDH: internal reference gene.
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IκB: inhibitor of -κB; IL-23: interleukin-23; LPS: lipopolysaccharide; LUC:
luciferase; M: macrophage; MKP-1: MAPK phosphatase 1; MM6: monomac
6 cells; Na3VO4: sodium orthovanadate; NF-κB: nuclear factor -κB; NK:
natural killer cell; PBS: phosphate buffered saline; TLR: Toll-like receptor
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